TCR2 THERAPEUTICS INC's ticker is TCRR and the CUSIP is 87808K106. A total of 93 filers reported holding TCR2 THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $467,000 | -38.0% | 259,672 | 0.0% | 0.01% | -33.3% |
Q2 2022 | $753,000 | +5.0% | 259,672 | 0.0% | 0.01% | +50.0% |
Q1 2022 | $717,000 | -64.1% | 259,672 | -39.3% | 0.01% | -62.5% |
Q4 2021 | $1,995,000 | -80.7% | 428,088 | -64.7% | 0.02% | -80.2% |
Q3 2021 | $10,327,000 | -38.7% | 1,213,498 | +18.1% | 0.08% | -36.2% |
Q2 2021 | $16,855,000 | -20.8% | 1,027,128 | +6.6% | 0.13% | -20.1% |
Q1 2021 | $21,276,000 | -41.1% | 963,606 | -17.4% | 0.16% | -43.2% |
Q4 2020 | $36,102,000 | +45.4% | 1,167,220 | -4.5% | 0.28% | +18.1% |
Q3 2020 | $24,825,000 | +19.2% | 1,221,699 | -9.9% | 0.24% | +10.2% |
Q2 2020 | $20,828,000 | +97.5% | 1,356,010 | -0.5% | 0.22% | +55.8% |
Q1 2020 | $10,547,000 | -41.8% | 1,362,653 | +7.3% | 0.14% | -14.3% |
Q4 2019 | $18,132,000 | +7.1% | 1,269,766 | +12.7% | 0.16% | -4.7% |
Q3 2019 | $16,928,000 | +143.7% | 1,126,307 | +132.1% | 0.17% | +152.2% |
Q2 2019 | $6,945,000 | -15.3% | 485,332 | +3.1% | 0.07% | -13.0% |
Q1 2019 | $8,204,000 | – | 470,698 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
MPM BioImpact LLC | 6,741,964 | $208,528,000 | 18.01% |
MPM ASSET MANAGEMENT LLC | 4,050,865 | $125,293,000 | 17.73% |
Consonance Capital Management LP | 584,885 | $71,268,000 | 6.66% |
SILVERARC CAPITAL MANAGEMENT, LLC | 136,000 | $4,206,000 | 2.44% |
Redmile Group, LLC | 2,832,888 | $87,621,000 | 1.06% |
Altium Capital Management LP | 73,991 | $2,289,000 | 0.86% |
PFM Health Sciences, LP | 775,794 | $23,995,000 | 0.84% |
Soleus Capital Management, L.P. | 199,867 | $6,182,000 | 0.82% |
MOODY ALDRICH PARTNERS LLC | 123,639 | $3,824,000 | 0.62% |
Sofinnova Investments, Inc. | 333,707 | $10,322,000 | 0.61% |